Abstract
In recent years with the development of targeted agents such as bevacizumab, sunitinib, sorafenib, temsirolimus, and everolimus, the treatment of metastatic renal cell carcinoma has changed dramatically. In clinical practice, sunitinib and bevacizumab are reserved for first-line treatment, but despite various guidelines, optimal treatment is still uncertain. We present, for the first time, a case of a good response to second-line bevacizumab and interferon-α in a patient who failed classical sunitinib treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 210-213 |
| Number of pages | 4 |
| Journal | Anti-Cancer Drugs |
| Volume | 21 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Feb 2010 |
Fingerprint
Keywords
- Bevacizumab
- Interferon
- Renal cancer
- Sunitinib
- Targeted therapy
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
- Cancer Research
- Oncology
Cite this
Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma. / Pastorelli, Davide; Zustovich, Fable; Faggioni, Giovanni; Zovato, Stefania; Donach, Martin; Nicoletto, Ornella; Farina, Miriam; Furini, Lara; Ceravolo, Renato; Carli, Paolo; Lombardi, Giuseppe.
In: Anti-Cancer Drugs, Vol. 21, No. 2, 02.2010, p. 210-213.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Good response to second-line bevacizumab and interferon-α in a sunitinib-refractory patient with metastatic renal cell carcinoma
AU - Pastorelli, Davide
AU - Zustovich, Fable
AU - Faggioni, Giovanni
AU - Zovato, Stefania
AU - Donach, Martin
AU - Nicoletto, Ornella
AU - Farina, Miriam
AU - Furini, Lara
AU - Ceravolo, Renato
AU - Carli, Paolo
AU - Lombardi, Giuseppe
PY - 2010/2
Y1 - 2010/2
N2 - In recent years with the development of targeted agents such as bevacizumab, sunitinib, sorafenib, temsirolimus, and everolimus, the treatment of metastatic renal cell carcinoma has changed dramatically. In clinical practice, sunitinib and bevacizumab are reserved for first-line treatment, but despite various guidelines, optimal treatment is still uncertain. We present, for the first time, a case of a good response to second-line bevacizumab and interferon-α in a patient who failed classical sunitinib treatment.
AB - In recent years with the development of targeted agents such as bevacizumab, sunitinib, sorafenib, temsirolimus, and everolimus, the treatment of metastatic renal cell carcinoma has changed dramatically. In clinical practice, sunitinib and bevacizumab are reserved for first-line treatment, but despite various guidelines, optimal treatment is still uncertain. We present, for the first time, a case of a good response to second-line bevacizumab and interferon-α in a patient who failed classical sunitinib treatment.
KW - Bevacizumab
KW - Interferon
KW - Renal cancer
KW - Sunitinib
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=76149119094&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76149119094&partnerID=8YFLogxK
U2 - 10.1097/CAD.0b013e3283340d1f
DO - 10.1097/CAD.0b013e3283340d1f
M3 - Article
C2 - 19952729
AN - SCOPUS:76149119094
VL - 21
SP - 210
EP - 213
JO - Anti-Cancer Drugs
JF - Anti-Cancer Drugs
SN - 0959-4973
IS - 2
ER -